UroGen Pharma Ltd (URGN NASDAQ) stock market data APIs
$18.9522
-1.38(-7.3%)
as of October 24, 2025
Try our APIs with
free plan!
UroGen Pharma Ltd Financial Data Overview
Price chart is built with
Anychart
UroGen Pharma Ltd. engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; and Jelmyto for pyelocalyceal solution. The company's lead product candidate are UGN-102 for pyelocalyceal solution; UGN-103, which is in phase 3 of clinical trial for intravesical solution; and UGN-104 that is in phase 3 of clinical trial for pyelocalyceal solution designed for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC). It is also developing UGN-301, UGN-301+ UGN 201, and UGN-301+gemcitabine that are in phase 1 of clinical trial for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 and UGN-104. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.
Prev. Close
18.9522
Open
17.5733
High
19.2541
Low
17.3458
52 wk Range
3.42-21.71
Market Cap
878 M
Shares Outstanding
46 264 K
Revenue
94 238 K
EPS
-1.05
Beta
1.018
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with UroGen Pharma Ltd (top by weight)
Ticker
100-day Price Change
Weight
ISRCF.US
iShares V Public Limited Company - iShares S&P 500 Information Technology Sector UCITS ETF
4.83
(12.79%)
0.18
ISRWF.US
iShares II Public Limited Company - iShares J.P. Morgan $ Emerging Markets Bond UCITS ETF
6.08
(6.99%)
0.17
ISRNF.US
iShares V Public Limited Company - iShares S&P 500 Consumer Discretionary Sector UCITS ETF
0.88
(5.74%)
0.17
ISRIF.US
iShares IV Public Limited Company - iShares $ Treasury Bond 20+yr UCITS ETF
0.3
(9.67%)
0.17
ISRZF.US
iShares II Public Limited Company - iShares $ High Yield Corporate Bond UCITS ETF
2.43
(2.56%)
0.17
ISRHF.US
iShares V Public Limited Company - iShares S&P 500 Energy Sector UCITS ETF
0.43
(4.8%)
0.09
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get UroGen Pharma Ltd data using free add-ons & libraries
Get UroGen Pharma Ltd Fundamental Data
UroGen Pharma Ltd Fundamental data includes:
- Net Revenue: 94 238 K
- EBITDA: -122 177 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-08-07
- EPS/Forecast: -0.83
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
UroGen Pharma Ltd News
New
ZUSDURI™ Clinical Review Published in Reviews in Urology™ Highlights Durable Efficacy and Manageable Safety Profile in Recurrent Low-Grade, Intermediate-Risk Non–Muscle Invasive Bladder Cancer
PRINCETON, N.J., Oct. 02, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company focused on developing and commercializing innovative solutions for urothelial and specialty ca...
Summit draws Neutral view on risk/reward setup as Piper initiates biotech cancer names
[Wall Street sign in Lower Manhattan, NYC] georgeclerk Piper Sandler launched the coverage of a raft of cancer-focused biotechs with bullish views on Monday while issuing a Neutral recommendation on ...
UroGen Pharma CMO Schoenberg sells $176k in shares
Mark Schoenberg, Chief Medical Officer of UroGen Pharma Ltd (NASDAQ:URGN), a company with impressive gross margins of 88.5% and a market capitalization of $902 million, sold 10,000 ordinary shares of ...
Sector Update: Health Care Stocks Decline Late Afternoon
Health care stocks were slipping late Thursday afternoon, with the NYSE Health Care Index down 1% an PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscri...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
